Document Detail

Will warfarin soon be passé? New approaches to stroke prevention in atrial fibrillation.
MedLine Citation:
PMID:  18594479     Owner:  NLM     Status:  MEDLINE    
Atrial fibrillation (AF) is the most common cause for thromboembolic stroke. Oral anticoagulation with warfarin is still the most effective therapy in patients with AF, who are at an increased risk for stroke. Nevertheless, warfarin therapy has several limitations; therefore, new anticoagulants like warfarin analogs, thrombin inhibitors, or factor Xa inhibitors have been developed. Some of them are currently being tested in phase III trials in patients with AF. Furthermore, the pathophysiology of prothrombotic endocardial remodeling in fibrillating atria suggests that angiotensin II increases prothrombotic expression of vascular adhesion molecules at the atrial endocardium. Thus, novel anticoagulants or hybrid therapy with a combination of anticoagulants with inhibitors of endocardial remodelling like angiotensin II receptor blockers appear to be attractive future perspective approaches.
Matthias Hammwöhner; Andreas Goette
Related Documents :
9890719 - Successful coronary stent implantation in a patient with primary antiphospholipid syndr...
17574129 - 3d and 2d delayed-enhancement magnetic resonance imaging for detection of myocardial in...
7473489 - Catastrophic antiphospholipid syndrome with fatal acute course in rheumatoid arthritis.
10853939 - Correlation of clinical and neuroradiological findings in down-gaze palsy.
12126819 - Aspirin and coumadin after acute coronary syndromes (the aspect-2 study): a randomised ...
10915479 - The emergency use of recombinant hirudin in cardiopulmonary bypass.
8349829 - Bioenergetic abnormalities associated with severe left ventricular hypertrophy.
16415069 - Predicting prognosis in stable angina--results from the euro heart survey of stable ang...
61929 - Experiences with the hematoxylin basic fuchsin picric acid staining method for morpholo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  52     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-22     Completed Date:  2008-11-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  18-27     Citation Subset:  IM    
Division of Cardiology, University Hospital Magdeburg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / therapeutic use*
Atrial Fibrillation / complications,  drug therapy*
Factor Xa / antagonists & inhibitors
Fibrinolytic Agents / therapeutic use
Receptors, Angiotensin / antagonists & inhibitors
Stroke / etiology,  prevention & control*
Thrombin / antagonists & inhibitors
Warfarin / analogs & derivatives*,  therapeutic use*
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Receptors, Angiotensin; 81-81-2/Warfarin; EC; EC Xa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot...
Next Document:  Therapeutic considerations in applying rate control therapy for atrial fibrillation.